Cited by 1,949Cancer-related Molecular PathwaysSarcoma Diagnosis and TreatmentHeat shock proteins research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B.·1992·Nature

Open this paper in CoChat — free account

Abstract

Despite extensive data linking mutations in the p53 gene to human tumorigenesis, little is known about the cellular regulators and mediators of p53 function. MDM2 is a strong candidate for one such cellular protein; the MDM2 gene was originally identified by virtue of its amplification in a spontaneously transformed derivative of mouse BALB/c cells and the MDM2 protein subsequently shown to bind to p53 in rat cells transfected with p53 genes. To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene. Here we show that recombinant-derived human MDM2 protein binds human p53 in vitro, and we use MDM2 clones to localize the human MDM2 gene to chromosome 12q13-14. Because this chromosomal position appears to be altered in many sarcomas, we looked for changes in human MDM2 in such cancers. The gene was amplified in over a third of 47 sarcomas, including common bone and soft tissue forms. These results are consistent with the hypothesis that MDM2 binds to p53, and that amplification of MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanism of tumorigenesis parallels that for virally-induced tumours, in which viral oncogene products bind to and functionally inactivate p53.

Integrity signals

Registry

Crossref · 10.1038/358080a0

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512
Self-citation
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citation
A simple and very efficient method for generating cDNA libraries
Gubler, U., & Hoffman, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90230-5 · Cited by 4,461
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citation
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,828
Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers
Fearon, E. R., Cho, K. R., Nigro, J. M., Kern, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., et al. (1990) · Science · doi:10.1126/science.2294591 · Cited by 1,760
Self-citation
Rapid transfer of DNA from agarose gels to nylon membranes
Reed, K. C., & Mann, D. A. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.20.7207 · Cited by 1,731
Casein kinase 2: An ‘eminence grise’ in cellular regulation?
Pinna, L. A. (1990) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(90)90098-x · Cited by 920

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 4

Hinds, P. W. et al. Cell Growth Differ. 1, 571–580 (1990).
Momand, J., Zambetti, G. P., Olson, D. C., George, D. L. & Levine, A. J. Cell (in the press).
Meltzer, P. S. et al. Cell Growth Differ. 2, 495–501 (1991).
Vogelstein, B. et al. Cancer Res. 47, 4806–4813 (1987).

Sorted by citations

Items 201–300 of 999

Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P., & Malkin, D. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117834 · Cited by 218
An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction
Macias, E., Jin, A., Deisenroth, C., Bhat, K., Mao, H., Lindström, M. S., & Zhang, Y. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.007 · Cited by 214
Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity
Shi, D., & Gu, W. J. (2012) · Genes & Cancer · doi:10.1177/1947601912455199 · Cited by 220
Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene
Chen, J., Lin, J., & Levine, A. J. (1995) · Molecular Medicine · doi:10.1007/bf03401562 · Cited by 214
Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms.
Sreekantaiah, C., Ladanyi, M., Rodrı́guez, E., & Chaganti, R. S. K. (1994) · PubMed Central · Cited by 214
Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers, J. E., Cassel, S., & George, D. L. (1997) · PubMed · Cited by 210
Self-citation
A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation
Lutzker, S. G., & Levine, A. J. (1996) · Nature Medicine · doi:10.1038/nm0796-804 · Cited by 206
What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?
Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207
Oncogene amplification in solid tumors
Schwab, M. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0126 · Cited by 207
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression
Minsky, N., & Oren, M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.016 · Cited by 204
Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
García‐Alonso, L., Iorio, F., Matchan, A., Fonseca, N. A., Jaaks, P., Peat, G., Pignatelli, M., Falcone, F., Benes, C. H., Dunham, I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1679 · Cited by 199
The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma
Du, M., Peng, H., Singh, N., Isaacson, P. G., & Pan, L. (1995) · Blood · doi:10.1182/blood.v86.12.4587.bloodjournal86124587 · Cited by 198
Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns
Sastre‐Garau, X., Jouve, M., Asselain, B. J. R., Vincent‐Salomon, A., Beuzeboc, P., Dorval, T., Durand, J. C., Fourquet, A., & Pouillart, P. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1 · Cited by 422
Phosphorylation of HDM2 by Akt
Ashcroft, M., Ludwig, R. L., Woods, D. B., Copeland, T. D., Weber, H. O., MacRae, E. J., & Vousden, K. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205276 · Cited by 197
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196
High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?
Crook, T., Nicholls, J. M., Brooks, L. A., O’Nions, J., & Allday, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203656 · Cited by 193
Mdm2: The Ups and Downs
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193
Malignant melanoma: modern black plague and genetic black boxPreprint
Chin, L., Merlino, G. T., & DePinho, R. A. (1998) · Genes & Development · doi:10.1101/gad.12.22.3467 · Cited by 195
More genes in fish?
Wittbrodt, J., Meyer, A., & Schartl, M. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199806)20:6 · Cited by 283
E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.
Kowalik, T. F., DeGregori, J. V., Leone, G. W., Jakoi, L., & Nevins, J. R. (1998) · PubMed · Cited by 190
Activation of the cryptic DNA binding function of mutant forms of p53
Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 190
Mdmx as an essential regulator of p53 activity
Marine, J., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 189
Recent Advances in p53 Research and Cancer Treatment
Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 191
Alterations of thep53, Rb andMDM2 genes in osteosarcoms
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B. C., & Koefflar, H. P. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213553 · Cited by 188
The p53 gene and its role in human brain tumors
Bögler, O., Huang, H., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 189
Targeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 190
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
Volpert, O. V., Lawler, J., & Bouck, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6343 · Cited by 185
Enhanced Mdm2 activity inhibits pRB function via ubiquitin‐dependent degradation
Uchida, C., Miwa, S., Kitagawa, K., Hattori, T., Isobe, T., Otani, S., Oda, T., Sugimura, H., Kamijo, T., Ookawa, K., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600486 · Cited by 191
The p53 tumour suppressor gene
Steele, R. J., Thompson, A. M., Hall, P. A., & Lane, D. P. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00910.x · Cited by 185
c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.
Reisman, D., Elkind, N. B., Roy, B., Beamon, J., & Rotter, V. (1993) · PubMed · Cited by 182
Complex composition and co‐amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well‐differentiated liposarcoma
Pédeutour, F., Suijkerbuijk, R. F., Forus, A., Gaal, J., Klundert, W. V. D., Coindre, J., Nicolò, G., Collin, F., Haelst, U., Huffermann, K., et al. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870100203 · Cited by 182
MDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in Angiosarcomas
Zietz, C., Rössle, M., Haas, C., Sendelhofert, A., Hirschmann, A., Stürzl, M., & Löhrs, U. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65729-x · Cited by 180
A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect
Bond, G. L., Hu, W., & Levine, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0825 · Cited by 176
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 178
ch-IAP1, a Member of the Inhibitor-of-Apoptosis Protein Family, Is a Mediator of the Antiapoptotic Activity of the v-Rel Oncoprotein
You, M. J., Ku, P., Hrdličková, R., & Bose, H. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7328 · Cited by 176
Impaired Nonhomologous End-Joining Provokes Soft Tissue Sarcomas Harboring Chromosomal Translocations, Amplifications, and Deletions
Sharpless, N. E., Ferguson, D. O., O’Hagan, R. C., Castrillón, D. H., Lee, C., Farazi, P. A., Alson, S., Fleming, J., Morton, C. C., Frank, K. M., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00425-7 · Cited by 173
Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors
Cin, P. D., Kools, P., Sciot, R., Wever, I. D., Damme, B. V., de Ven, W. V., & BERGHE, H. V. D. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90001-3 · Cited by 175
Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.
Reifenberger, G., Ichimura, K., REIFENBERGER, J., ELKAHLOUN, A. G., Meltzer, P. S., & Collins, V. P. (1996) · PubMed · Cited by 175
Self-citation
The Role ofP53andMDM2Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma
Yuan, H., Miao, X., Zhang, X., Ding, F., Luo, A., Guo, Y., Tan, W., Liu, Z., & Lin, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1460 · Cited by 173
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
The role of p53-target genes in human cancer
Tokino, T., & Nakamura, Y. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00051-7 · Cited by 179
Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
A novel p53‐inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis
Israeli, D., Tessler, E., Haupt, Y., Elkeles, A., Wilder, S., Amson, R. B., Telerman, A., & Oren, M. (1997) · The EMBO Journal · doi:10.1093/emboj/16.14.4384 · Cited by 172
Apoptosis and inflammation
Haanen, C., & Vermes, I. (1995) · Mediators of Inflammation · doi:10.1155/s0962935195000020 · Cited by 177
Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene
Wu, L., & Levine, A. J. (1997) · Molecular Medicine · doi:10.1007/bf03401691 · Cited by 172
Genotoxic and non-genotoxic pathways of p53 induction
Pluquet, O., & Hainaut, P. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00698-x · Cited by 177
Gene amplification and tumor progression
Brison, O. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90020-d · Cited by 171
The Transactivation Domains of the p53 ProteinPreprint
Raj, N., & Attardi, L. D. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 178
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Inhibition of p53 Transactivation Function by the Human T-Cell Lymphotropic Virus Type 1 Tax Protein
Pise-Masison, C. A., Choi, K. S., Radonovich, M. F., Dittmer, J., Kim, S., & Brady, J. N. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1165-1170.1998 · Cited by 172
The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T., & Saito, H. (1994) · Blood · doi:10.1182/blood.v84.9.3158.3158 · Cited by 174
Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature
Bridge, J. A., Nelson, M., McComb, E. N., McGuire, M. H., Rosenthal, H. G., Vergara, G. G., Maale, G. E., Spanier, S. S., & Neff, J. R. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00306-8 · Cited by 169
Prognostic significance of TP53 alterations in breast carcinoma
Andersen, T., Holm, R., Nesland, J. M., Heimdal, K., Ottestad, L., & Børresen‐Dale, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.383 · Cited by 162
Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas
Baur, A. S., Shaw, P., Hirt‐Burri, N., Delacrétaz, F., Bosman, F. T., & Chaubert, P. (1999) · Blood · doi:10.1182/blood.v94.5.1773 · Cited by 168
Mdm-2: “big brother” of p53
Momand, J. A., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3 · Cited by 167
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma
Sandberg, A. A. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.08.005 · Cited by 167
Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway
Morimitsu, Y., Nakajima, M., Hisaoka, M., & Hashimoto, H. (2000) · Apmis · doi:10.1034/j.1600-0463.2000.d01-105.x · Cited by 167
Targeting protein–protein interactions by rational design: mimicry of protein surfaces
Fletcher, S., & Hamilton, A. D. (2006) · Journal of The Royal Society Interface · doi:10.1098/rsif.2006.0115 · Cited by 167
The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain
Elenbaas, B., Dobbelstein, M., Roth, J. C., Shenk, T. E., & Levine, A. J. (1996) · Molecular Medicine · doi:10.1007/bf03401903 · Cited by 164
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161
Loss of Oncogenic H-ras-Induced Cell Cycle Arrest and p38 Mitogen-Activated Protein Kinase Activation by Disruption of Gadd45a
Bulavin, D. V., Kovalsky, O., Hollander, M. C., & Fornace, A. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.11.3859-3871.2003 · Cited by 161
Visualization and targeted disruption of protein interactions in living cells
Herce, H. D., Deng, W., Helma, J., Leonhardt, H., & Cardoso, M. C. (2013) · Nature Communications · doi:10.1038/ncomms3660 · Cited by 166
Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
Qi, S., Cheng, G., Cheng, X., Xu, Z., Xu, B., Zhang, W., & Qin, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00233 · Cited by 167
IκB Kinase-Independent IκBα Degradation Pathway: Functional NF-κB Activity and Implications for Cancer Therapy
Tergaonkar, V., Bottero, V., Ikawa, M., Li, Q., & Verma, I. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8070-8083.2003 · Cited by 162
Human Papillomavirus Oncoproteins E6 and E7 Independently Abrogate the Mitotic Spindle Checkpoint
Thomas, J. T., & Laimins, L. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1131-1137.1998 · Cited by 161
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159
A new multicolor-FISH approach for the characterization of marker chromosomes: centromere-specific multicolor-FISH (cenM-FISH)
Nietzel, A., Rocchi, M., Starke, H., Heller, A., Fiedler, W., Włodarska, I., Lončarević, I., Beensen, V., Claussen, U., & Liehr, T. (2001) · Human Genetics · doi:10.1007/s004390100459 · Cited by 159
A Human Herpesvirus MicroRNA Inhibits p21 Expression and Attenuates p21-Mediated Cell Cycle Arrest
Gottwein, E., & Cullen, B. R. (2010) · Journal of Virology · doi:10.1128/jvi.00202-10 · Cited by 161
ICI 182,780 (Faslodex?)
Howell, A., Osborne, C. K., Morris, C. Q., & Wakeling, A. E. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4 · Cited by 408
SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.Preprint
Oliner, J., Andresen, J. M., Hansen, S. K., Zhou, S., & Tjian, R. (1996) · Genes & Development · doi:10.1101/gad.10.22.2903 · Cited by 159
Self-citation
Genetic polymorphisms in cell cycle regulatory genesMDM2 andTP53 are associated with susceptibility to lung cancer
Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., & Lin, D. (2005) · Human Mutation · doi:10.1002/humu.20277 · Cited by 156
p53 is balancing development, differentiation and de-differentiation to assure cancer prevention
Molchadsky, A., Rivlin, N., Brosh, R., Rotter, V., & Sarig, R. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq101 · Cited by 161
Proteasome system of protein degradation and processing
Sorokin, A. V., Kim, E. R., & Ovchinnikov, L. P. (2009) · Biochemistry (Moscow) · doi:10.1134/s000629790913001x · Cited by 163
Mutations of the p53 gene do not occur in testis cancer.
Peng, H., Hogg, D., Malkin, D. M., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M. A. S., Buchanan, J., & Goss, P. E. (1993) · PubMed · Cited by 154
Apoptosis, cancer and the p53 tumour suppressor gene
Lee, J. M., & Bernstein, A. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00665797 · Cited by 149
Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency
Hardcastle, I. R., Liu, J., Valeur, E., Watson, A. F., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C. J., Endicott, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 153
Isolation and Identification of the Human Homolog of a New p53-Binding Protein, Mdmx
Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y. F., Steegenga, W. T., Merckx, G., van Ham, R. C. A., van Oordt, C. W. M. D. H., van der Eb, A. J., & Jochemsen, A. G. (1997) · Genomics · doi:10.1006/geno.1997.4775 · Cited by 152
Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation
Lindström, M. S., Jin, A., Deisenroth, C., Wolf, G. W., & Zhang, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 149
STAT‐1: a novel regulator of apoptosis
Stephanou, A., & Latchman, D. S. (2003) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2003.00363.x · Cited by 152
Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
Wunder, J. S., Eppert, K., Burrow, S., Gogkoz, N., Bell, R. S., & Andrulis, I. L. (1999) · Oncogene · doi:10.1038/sj.onc.1202346 · Cited by 152
Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes.
Zauberman, A., Barak, Y., Ragimov, N., Levy, N., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05941.x · Cited by 151
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 156
p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein
Poller, D. N., Roberts, E., Bell, J. A., Elston, C. W., Blamey, R. W., & Ellis, I. O. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90157-c · Cited by 150
p53 gene mutations in pituitary adenomas: rare events
Levy, A., Hall, L., Yeudall, W. A., & Lightman, S. L. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02797.x · Cited by 148
The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis
Brown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction
Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 149
Self-citation
Small-Molecule Inhibitors of the MDM2-p53 Protein−Protein Interaction Based on an Isoindolinone Scaffold
Hardcastle, I. R., Ahmed, S. U., Atkins, H., Farnie, G., Golding, B. T., Griffin, R. J., Guyenne, S., Hutton, C., Källblad, P., Kemp, S. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601194 · Cited by 149
Apoptosis and Programmed Cell Death in Health and Disease
Vermes, I., & Haanen, C. (1994) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)60336-4 · Cited by 148
Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions
Moretti, S., Pinzi, C., Spallanzani, A., Berti, E., Chiarugi, A., Mazzoli, S., Fabiani, M., Vallecchi, C., & Herlyn, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990420)84:2 · Cited by 98
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 149
Inflammation, carcinogenesis and cancer
Fitzpatrick, F. A. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00102-3 · Cited by 146
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation
Fisher, C., Gillett, C. E., Vojtěšek, B., Barnes, D. M., & Millis, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.4 · Cited by 145
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1
Inoue, K., Roussel, M. F., & Sherr, C. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3993 · Cited by 144
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 151
p53 and MDM2 alterations in osteosarcomas
Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8 · Cited by 147
A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway
Mullenders, J., Fabius, A. W. M., Madiredjo, M., Bernards, R., & Beijersbergen, R. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004798 · Cited by 146
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 146

Authors: Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B.
Affiliations: University of Michigan (US)
Johns Hopkins University (US)
University of Pennsylvania (US)
ORCID: Oliner, J. D.
Kinzler, K. W.
Meltzer, P. S.
George, D. L.
Vogelstein, B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1992-07
Volume: 358
Issue: 6381
Pages: 80-83
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/358080a0
OpenAlex: W2091151265
Cited by: 1,949
References: 32
Citations by year: 2026: 14 · 2025: 22 · 2024: 23 · 2023: 27 · 2022: 25 · 2021: 36 · 2020: 37 · 2019: 32 · 2018: 20 · 2017: 37 · 2016: 52 · 2015: 46 · 2014: 63 · 2013: 46 · 2012: 58
FWCI: 52.87
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Deep Blue (University of Michigan) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, gene amplification, sarcoma, p53 binding, tumor suppressor inactivation, bone sarcoma, soft tissue sarcoma, viral oncogenes, carcinogenesis
MeSH terms: Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 12, Cloning, Molecular, DNA, Gene Amplification, Humans, Molecular Sequence Data, Neoplasm Proteins, Neoplasms, Nuclear Proteins, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Sequence Homology, Nucleic Acid, Gene Expression, Tumor Suppressor Protein p53, Sequence Alignment, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amplification of a gene encoding a p53-associated protein in human sarcomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks